Barr Labs v. Sullivan
Supreme Court lets stand on Oct. 14 the April 16 D.C. federal appellate court decision denying Barr's petition to force FDA to complete ANDA reviews within 180 days. The latest decision was made without comment. The April decision stated that, although FDA's failure to review ANDAs in 180 days does violate a statutory limit, the court lacks the power to force FDA to process ANDAs within the deadline ("The Pink Sheet" April 22, p. 10)....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth